NASDAQ:HOOKHookipa Pharma Stock Price, Forecast & News

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HOOK shares have increased by 11.4% and is now trading at $10.30. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hookipa Pharma.

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Hookipa Pharma.

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.01. The company earned $3.70 million during the quarter, compared to analysts' expectations of $4.36 million. Hookipa Pharma had a negative net margin of 333.02% and a negative return on equity of 36.53%. View Hookipa Pharma's earnings history.

2 Wall Street analysts have issued 1 year target prices for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 84.5% from the stock's current price. View analysts' price targets for Hookipa Pharma.

Headlines about HOOK stock have been trending negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hookipa Pharma earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Hookipa Pharma.

Hookipa Pharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 723,700 shares, an increase of 300.5% from the May 31st total of 180,700 shares. Based on an average trading volume of 78,700 shares, the days-to-cover ratio is currently 9.2 days. Approximately 6.2% of the shares of the company are short sold. View Hookipa Pharma's Current Options Chain.

Some companies that are related to Hookipa Pharma include Legend Biotech (PLRX), Phathom Pharmaceuticals (PHAT), Retrophin (RTRX), Generation Bio (GBIO), Gossamer Bio (GOSS), Endo International (ENDP), Cara Therapeutics (CARA), ImmunoGen (IMGN), Dynavax Technologies (DVAX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Legend Biotech (AMTI), Assembly Biosciences (ASMB), Stoke Therapeutics (STOK) and Morphic (MORF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Atreca (BCEL), Homology Medicines (FIXX), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Stoke Therapeutics (STOK), Akero Therapeutics (AKRO) and Tcr2 Therapeutics (TCRR).

(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HOOK stock can currently be purchased for approximately $10.30.

Hookipa Pharma has a market capitalization of $224.80 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Hookipa Pharma employs 56 workers across the globe.

The official website for Hookipa Pharma is www.hookipapharma.com.

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]